Remove

Doc description: Information Disclosure Statement (IDS) Filed Under the Paperwork Reduction Act of 1995, no persons are reque

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number			10599663		
	Filing Date		2006-10-04		
	First Named Inventor Dusa		n Miljkovic		
	Art Unit		1655		
Examiner Name Miche		Miche	ele C. Flood		
	Attamen Dealest Numb		100700 0022110		

Examiner Initial*	ner Cite No Patent Number Kind Code! Issue Date Name of Patentee or Ap			Rele	es,Columns,Lines where want Passages or Releves es Appear					
	1	5178832		1993-01	l-12	Phillips et al.				
If you wisi	h to ad	ld additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applican of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20030152612		2003-08	l-14	Pugliese et al.				
If you wish	h to ad	d additional U.S. Publ	ished Ap	plication	citatio	n information p	olease click the Ad	d butto	on. Add	
				FOREIG	SN PA1	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite Foreign Document No Number <sup>3</sup>		Country Kind Code <sup>2</sup> i Code			Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	т.
	1	1 2004/098320		wo		2004-11-18	VDF Futureceuticals			
	2	99114866.5	CN			2000-11-22	Jiankang et al.			
	3	1593735	EΡ			2004-05-07	Biodyn GmbH			

U.S. PATENTS

#### 

If you wisl	h to a	dd add	itional Foreign Patent Document citation information please click t	he Add button	Add	
			NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of (book, magazine), journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number publisher, city and/or country where publisher.						ТБ
	1		DS, K., "Home Roasting Coffee: Romance and Revival", webpage from A sher St. Martin's Press, US.	mazon.com with	link to book, 1996,	
If you wis	h to a	dd add	litional non-patent literature document citation information please of	lick the Add bu	utton Add	_
			EXAMINER SIGNATURE			
Examiner	Signa	ture	Date 0	Considered		

1 See Kind Code of USPTO Patent Documents at year USPTO\_GOLY or MEPP 901.64. I Enter office that issued the document, by the low-letter (SWIPO) Standard \$13.3. I See Toughanese patent fourment, he included not deep variet for less price the series represent he serial run-letter patent document. I Kind of document by the appropriate symbols as indicated on the document under WIPO Standard \$11.6 if possible. Tappicant is to place a check mark here if Engine Israques presentation is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10599663		
Filing Date		2006-10-04		
First Named Inventor	Dusar	n Miljkovic		
Art Unit		1655		
Examiner Name	Miche	ele C. Flood		
Attorney Docket Number		100700.0033US		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 97 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CPR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CPR 1.97(c)(c)

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

# SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the agriculture.							
Signature	/Martin Fessenmaier/	Date (YYYY-MM-DD)	2012-01-26				
Name/Print	Martin Fessenemaler	Registration Number	46697				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbrary, and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested more considerable or the patient of the patient of

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.